Investor Presentation

October 2026

Senores
Committed to Global Wellness!

Safe Harbor

This presentation and the accompanying slides (the “Presentation”), which have been prepared by **Senores Pharmaceuticals Limited** (the “Company”), have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe for any securities, and shall not form the basis or be relied on in connection with any contract or binding commitment whatsoever. No offering of securities of the Company will be made except by means of a statutory offering document containing detailed information about the Company.

This Presentation has been prepared by the Company based on information and data which the Company considers reliable, but the Company makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this Presentation. This Presentation may not be all inclusive and may not contain all of the information that you may consider material. Any liability in respect of the contents of, or any omission from, this Presentation is expressly excluded.

Certain matters discussed in this Presentation may contain statements regarding the Company’s market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. These risks and uncertainties include, but are not limited to, the performance of the Indian economy and of the economies of various international markets, the performance of the industry in India and world-wide, competition, the company’s ability to successfully implement its strategy, the Company’s future levels of growth and expansion, technological implementation, changes and advancements, changes in revenue, income or cash flows, the Company’s market preferences and its exposure to market risks, as well as other risks. The Company’s actual results, levels of activity, performance or achievements could differ materially and adversely from results expressed in or implied by this Presentation. The Company assumes no obligation to update any forward-looking information contained in this Presentation. Any forward-looking statements and projections made by third parties included in this Presentation are not adopted by the Company and the Company is not responsible for such third-party statements and projections.

All Maps used in the presentation are not to scale. All data, information, and maps are provided "as is" without warranty or any representation of accuracy, timeliness or completeness.

Financial & Operational Highlights Q2 & H1FY27

Key Highlights – Q2 & H1FY27

Consistently strong delivery

REVENUE GROWTH		EBITDA GROWTH		EBITDA MARGIN EXPANSION		CASH FROM OPERATIONS	
25%	30%	38.4%	58.2%	~290 bps	~530 bps	₹38 Cr	₹31 Cr
Q2 FY27	H1 FY27	Q2 FY27	H1 FY27	Q2 FY27	H1 FY27	H1 FY27	H1 FY26

Strong EBITDA growth even while investing for the future

Q2 and H1 FY27 EBITDA grew 38.3% and 58.2% despite investments in Apnar (last 6 months) and ongoing investments in Zoraya & Amerisyn (revenues to ramp up over the next 12 months). Excluding these investments, which will reap future benefits, EBITDA growth would have been much higher.

What drives the H2 outlook

Robust approved & pipeline products

Strong growth visibility – H2 expected to be considerably better than H1 owing to anticipated launches

R&D intensity at 11% of revenue

R&D expenses stood at 11% of revenue in H1 FY27

Forward integration

Zoraya and Amerisyn to begin contributing to revenues from H2 FY27

Senores group companies

INDIA

Ratnatris Pharmaceuticals Pvt. Ltd. (A subsidiary of Senores Pharmaceuticals Ltd.)

APNAR PHARMA PVT. LTD. (A subsidiary of Senores Pharmaceuticals Ltd.)

USA

Senores Pharmaceuticals Inc. (Wholly Owned Subsidiary)

Havix Group Inc. D/B/A Aavis Pharmaceuticals (A subsidiary of Senores Pharmaceuticals Ltd.)

Zoraya Pharmaceuticals, LLC (A subsidiary of Senores Pharmaceuticals Inc.)

Amerisyn LLC (A subsidiary of Senores Pharmaceuticals Inc.)

Regulated Market Owned Product Portfolio & Visibility

	Owned ANDAs		Corresponding ANDA Products*	
	Q2FY26	Q2FY27	Q2FY26	Q2FY27
Approved ANDAs	34	64	81	207
Commercialized ANDAs	16	23	32	54
ANDAs Yet To Launch	18	41	49	153
Molecules Under Development	35	41	70	130

Key Highlights

- **Commercialized 3 new strengths** in Q2FY27 under existing ANDAs, including **2 being sold in the US for the first time** by any company.
- Received **approval** for 1 ANDA and 3 sANDA's in Q2FY27.
- 41 ANDAs with Corresponding 153 ANDA Products* to be launched
- Expecting **13 ANDAs with 41 strengths to be commercialized in government channel in H2FY27**.
- Robust Pipeline of 41 molecules with 130 unique strengths under development.

*ANDA Products represents individual strengths associated with an ANDA

CDMO / CMO & Emerging Market Opportunity

Senores
Committed to Global Wellness!

Regulated Markets

ANDAs

	Q2FY26	Q2FY27
CDMO/ CMO Commercialized Products	16	19
CDMO / CMO Pipeline Products	13	34

Corresponding ANDA Products*

	Q2FY26	Q2FY27
CDMO/ CMO Commercialized Products	32	46
CDMO / CMO Pipeline Products	45	108

Huge Opportunity

CDMO/CMO business focused on specialty, **government supplies** and **controlled substances**.


Uniquely positioned in USA & India to provide **end-to-end solutions** from development to commercialization.

Commercialized 3 more partner ANDAs and 12 Strengths in Q2FY27


Significantly **enhances efficiency, scale & utilization**, leading to **better operating leverage**.

Emerging Markets Portfolio

Approved Products



Products under Registration




Significant expansion of the **Approved and Pipeline** product portfolio across **40+ countries** creating a **strong runway for future growth.**


*ANDA Products represents individual strengths associated with an ANDA

Consolidated Financial Highlights – Q2 & H1FY27


Revenue (₹ Crs)




EBITDA (₹ Crs)




PAT (₹ Crs)




Gross Margin (%)



EBITDA Margin (%)



PAT Margin (%)



Segmental Financial Highlights – Q2 & H1FY27

Segment Revenue (₹ Crs)	Q2FY27	Q2FY26	Y-o-Y	H1FY27	H1FY26	Y-o-Y
Regulated Markets	**136.7**	106.9	***27.9%***	**264.5**	196.9	***34.3%***
Emerging Markets	**38.4**	31.7	***21.2%***	76.0	60.7	***25.3%***
Branded Generics	**9.5**	11.9	***-20.5%***	**17.5**	20.2	***-13.4%***
Others	**7.8**	3.4	***126.2%***	**14.6**	8.7	***67.2%***
Total Revenue	**192.3**	153.9	***24.9%***	**372.5**	286.5	***30.0%***

- **Regulated Markets -** EBIDTA Margin for H1 FY27 stood at ~42%. Regulated Markets contributed to **71% of total revenue** in H1FY27
- **Emerging Markets -** EBIDTA Margin for H1 FY27 stood at ~9%. Emerging Markets contributed **20% of total revenue** in H1FY27

Consolidated Profit & Loss Account – Q2 & H1FY27

Consolidated P&L (₹ Crs)	Q2FY27	Q2FY26	Y-o-Y	H1FY27	H1FY26	Y-o-Y
Revenue from Operations	**192.3**	**153.9**	***24.9%***	**372.5**	**286.5**	***30.0%***
Cost of Goods Sold	66.6	57.1		132.3	118.4	
Gross Profit	**125.8**	**96.9**	***29.8%***	**240.2**	**168.1**	***42.9%***
Gross Margin (%)	**65.4%**	**62.9%**	***250 bps***	**64.5%**	**58.7%**	***580 bps***
Employee Cost	32.4	29.6		62.3	51.3	
Other Expenses	35.7	25.6		66.5	46.4	
EBITDA	**57.7**	**41.7**	***38.3%***	**111.4**	**70.4**	***58.2%***
EBITDA Margin (%)	**30.0%**	**27.1%**	***290 bps***	**29.9%**	**24.6%**	***530 bps***
Other Income	8.9	13.2		11.8	22.0	
Depreciation	10.3	8.1		20.2	14.1	
Finance Cost	8.8	6.2		15.9	11.2	
PBT	**47.6**	**40.6**	***17.1%***	**87.0**	**67.1**	***29.7%***
Tax Charge / (Credit)	11.0	10.5		20.0	15.8	
Profit after Tax	**36.6**	**30.1**	***24.7%***	**67.0**	**51.3**	***32.6%***
PAT Margin (%)	**19.0%**	**19.5%**	***-50 bps***	**18.0%**	**17.9%**	***10 bps***
Minority Interest	(2.9)	(2.3)		(3.2)	(0.8)	
Profit after Tax and Minority Interest	**39.5**	**32.4**	***22.0%***	**70.2**	**52.1**	***34.7%***
PAT Margin (%) after Minority Interest	**20.5%**	**21.0%**	***-50 bps***	**18.9%**	**18.2%**	***70 bps***

Consolidated Balance Sheet

ASSETS (₹ Crs)	Sep-26	Mar-26
Non-Current Assets		
Property, Plant and Equipment	336.2	331.4
Capital Work-in-Progress	31.1	17.5
Right of Use Assets	23.7	13.9
Goodwill	46.6	46.6
Other Intangible Assets	109.1	106.8
Intangible Assets under Development	311.1	232.0
Investment Property	24.8	24.6
Financial Investments	5.9	4.3
Non-Current Financial Assets	18.9	10.2
Deferred Tax Assets (Net)	2.3	0.0
Other Non-Current Assets	4.7	4.2
Total Non-Current Assets	**914.3**	**791.4**
Current Assets		
Inventories	97.6	89.3
Trade Receivables	253.2	324.8
Cash & Cash Equivalents	18.0	45.6
Other Bank Balances	82.7	114.1
Other Current Financial Assets	224.3	172.7
Other Current Assets	90.5	66.0
Total Current Assets	**766.3**	**812.4**
Total ASSETS	**1,680.6**	**1,603.8**

EQUITY AND LIABILITIES (₹ Crs)	Sep-26	Mar-26
Equity		
Equity Share Capital	46.1	46.1
Other Equity	956.9	887.6
Total Shareholder's Fund	**1,002.9**	**933.6**
Non-Controlling Interest	28.6	30.9
Total Equity	**1,031.5**	**964.5**
Non-Current Liabilities		
Borrowings	212.9	194.9
Lease Liabilities	19.2	13.2
Provisions	5.4	6.6
Deferred tax liabilities (net)	0.0	0.6
Total Non-Current Liabilities	**237.5**	**215.3**
Current Liabilities		
Borrowings	181.6	132.2
Trade Payables	151.1	234.7
Lease Liabilities	3.1	1.8
Other Current Financial Liabilities	12.7	17.6
Other Current Liabilities	22.0	14.8
Provisions	7.2	2.7
Current Tax Liabilities (net)	33.9	20.2
Total Current Liabilities	**411.6**	**424.0**
Total EQUITY AND LIABILITIES	**1,680.6**	**1,603.8**

Consolidated Abridged Cash Flow Statement

Cash Flow Statement (₹ crs)	H1 FY27	H1 FY26
Profit/(Loss) Before Tax	**87.0**	**67.1**
Adjustments for Non-Cash and Non-Operational Expenses / (Incomes)	36.2	7.8
Operating Profit / (Loss) Before Working Capital Changes	**123.2**	**74.9**
Changes in Working Capital	(84.7)	(43.5)
Cash from Operations	**38.5**	**31.4**
Income Tax (Paid) / Refunded	(9.3)	(7.2)
Net Cash Flow from Operating Activities (A)	**29.2**	**24.2**
Net Cash Flow from Investing Activities (B)	**(112.2)**	**41.3**
Net Cash Flow from Financing Activities (C)	**55.4**	**(84.9)**
Net Change in Cash & Cash Equivalents during the Year (A+B+C)	**(27.6)**	**(19.4)**
Cash & Cash Equivalents at the Beginning of the Period	45.6	105.4
Cash & Cash Equivalents at the End of the Period	**18.0**	**86.0**

Update on Utilization of Funds from IPO

No.	Object as per Offer Document	Amount as proposed in Offer Document and as Revised (₹ Crs)	Amount utilized till 30th September 2026 (₹ Crs)	Amount unutilized as on 30th September 2026 (₹ Crs)
1	Investment in one of our Subsidiaries, Havix, to fund capital expenditure requirements for setting up a manufacturing facility for the production of sterile injections in our Atlanta Facility	41.98	6.98	35.00
2	Re-payment/pre-payment, in full or in part, of certain borrowings availed by our Company	73.10	73.10	0.00
3	Investment in our Subsidiary, namely, Havix, for re- payment/pre-payment in full or in part, of certain borrowings availed by such Subsidiaries	20.20	20.20	0.00
4	Funding the working capital requirements of our Company	43.26	43.26	0.00
5	Investment in our Subsidiaries, namely, Senores Pharma Inc. and Ratnatris Pharmaceuticals Pvt Ltd. to fund their working capital requirements	59.48	59.48	0.00
6	Funding inorganic growth through acquisition and other strategic initiatives and general corporate purposes	161.91	161.91	0.00
7	Offer expenses	35.04	34.99	0.05
8	Investment in subsidiary SPI to fund the acquisition of ANDAs	15.39	10.07	5.32
9	Investment in one of the subsidiaries, Apnar, to fund the capital expenditure requirements for expansion of its existing manufacturing facility in Vadodara	25.00	1.69	23.32
10	Investment in one of the subsidiaries, Havix, to fund the capital expenditure requirements for expansion of the existing OSD manufacturing facility in Atlanta	24.63	7.14	17.48
	Total	**500.00**	**418.83**	**81.17 #**

₹ 81.11 crores parked in ICICI Bank FD and ₹ 0.06 crores held in HDFC Bank Account.

Growth Strategies

Growth Strategies

Inorganic growth through **synergistic acquisitions**

Significantly enhance market presence in **North America** & **other Regulated Markets**

Integrated approach by enhancing capabilities for **backward integration**



Launch products with the **potential of NDA approval** in the **US**

Strategic alliance for **CMO/CDMO** in **Regulated Markets**

Expanding into new ventures of **Direct B2C** and **Government Sales**

About Senores Pharmaceuticals Limited

Introduction to Senores Pharmaceuticals

Brief Overview

Global Research driven **Formulation Focused** company engaged in **developing** & **manufacturing** of pharmaceutical products predominantly for the **Regulated Markets of the US, Canada, UK and others** across various **therapeutic areas**

Niche Product Identification

Company focusses on **identification, development** and **commercialization** of products

R&D Capabilities

Identification, development & manufacturing of diverse range of **specialty, underpenetrated & complex** pharmaceutical products across therapeutic areas and dosage forms

Manufacturing Facilities

1 USFDA approved Formulation facility in Atlanta, US
2 Formulation facilities in Gujarat, India – out of which 1 is USFDA approved
2 API manufacturing facilities in Gujarat, India

Partnerships

Partnerships with leading pharmaceutical companies across Regulated as well as Emerging Markets

At a Glance



Disclaimer: Map not to scale. All data, information, and maps are provided "as is" without warranty or any representation of accuracy, timeliness or completeness.

Corporate Structure

Senores Pharmaceuticals Inc.	**Senores Pharmaceuticals Inc.** Marketing cum ANDA Holding Company	US based company holding ANDAs and mutually exclusive marketing relationships with customers	100% Subsidiary
AAVIS PHARMACEUTICALS	**Aavis Pharmaceuticals** Manufacturing arm of our Regulated market offerings	Engaged in the Contract Development & Manufacturing of Generic Pharmaceutical Formulations for the US, Canada	73.28%[1] Subsidiary
Ratnatris Pharmaceuticals	**Ratnatris Pharmaceuticals Pvt Ltd.** Caters to Emerging Market	Development, Manufacturing and Marketing of Generic Pharmaceutical Formulations	69% Subsidiary
APNAR PHARMA PVT. LTD. (A subsidiary of Senores Pharmaceuticals Ltd.)	**Apnar Pharma Pvt. Ltd.** Caters to Regulated Market	Licensed Manufacturer Serving Regulated Markets. Operates a manufacturing facility at Gujarat with 5 ANDAs approved	75% Subsidiary
AMERISYN	Entered U.S. Federal Market via Strategic JV – **Amerisyn LLC**	Senores Pharma's U.S. JV, Amerisyn, enables direct access to high-barrier federal and defense markets, driving future growth.	70% stake
ZORAYA PHARMACEUTICALS	**Zoraya Pharmaceuticals LLC** is a B2C arm for our US Market	Forward integration for the products which are manufactured at Havix & Apnar and marketed in US market.	51% stake

Note 1 : 57.69% held by the holding company & 15.59% held by it's wholly owned subsidiary company named Senores Pharmaceuticals Inc

Key Events & Milestones

2017

Incorporated as "**Senores Pharmaceuticals Pvt. Ltd.**" in India.

2021

Entered into a new segment of API with **acquisition** of **Ratnagene Lifescience Pvt. Ltd.**[1]

2021

Incorporated a wholly owned subsidiary, **Senores Pharmaceuticals Inc** in the US

2023

Acquired majority stake in **Havix**, enhancing the ability to serve Regulated Markets through **USFDA approved facility** in **US**

2023

Consolidated presence in emerging markets by acquiring shares in **Ratnatris Pharmaceuticals Pvt. Ltd.**

2024

Successful Listing on Stock Exchanges in India on **BSE & NSE**

2025

Acquired a **51% stake in Zoraya Pharmaceuticals**, LLC (Nov 2025)
Acquired **75% stake in Apnar Pharmaceuticals Pvt. Ltd**

2026

Amerisyn LLC - Strategic **joint venture in the U.S**, for Federal and defense sector supplies

Note: 1: Now merged with Senores Pharmaceuticals Limited with the appointed date being January 1, 2024

Key Strengths of the Company

Senores
Committed to Global Wellness!

- Distinct **Specialty and Complex Product Portfolio** built in a short span for **Regulated Markets**
- **Direct access** to the **US Government supplies** through its subsidiary
- Enabling **Forward Integration** via our subsidiary, catering directly to **B2C** and **Veterinary market**
- **Strong R&D capabilities** driving differentiated portfolio of products
- **US FDA approved facility in the US & India** catering to the **Regulated** & **Semi-Regulated Markets**
  WHO- GMP compliant facility **in India** catering to **Emerging Markets**
- **Professional & Experienced** management teams for the diverse business verticals

Four Business Segments



FY26 Revenue

₹ 192 Crs

Regulated Markets Business

Primarily serves the **US, Canada** and **United Kingdom**

USFDA approved **facility in Atlanta, US and Gujarat, India**

Approved - **64** ANDAs with **207** Strengths

Commercialized – **23** ANDAs with **54** Strengths

Pipeline Products – **41** Molecules with **130** Strengths

AAVIS PHARMACEUTICALS

APNAR PHARMA PVT. LTD. (A subsidiary of Senores Pharmaceuticals Ltd.)

Senores Pharmaceuticals Inc.

AMERISYN

ZORAYA PHARMACEUTICALS

Emerging & Mid-Tier Markets Business

Develop & manufacture pharmaceutical products for the Emerging & Mid-Tier Markets

WHO-GMP approved **facility at Chhatral, Gujarat**

Present in **40+ Countries**

Approval for manufacturing facility from regulatory bodies of **10 Countries**

Ratnatris Pharmaceuticals

Product registration for **558 Products**

Product applications filed for **944 Products**

API Business

Manufacture APIs and caters to the **domestic market** and **SAARC countries**

Naroda facility compliant with Indian GMP

Commercialized **17 APIs**

Branded Generics Business

Supply of critical care injectables across **India** to various **hospitals** through the distributors

Field presence with **104 employees**

Launched **60 Products**

Presence in Regulated Markets through Long-term marketing arrangements

MARKETED PRODUCTS

Business Model

Identify, Develop & Commercialize specialty & complex niche products in mid-market range

- **Long-term Marketing & Distribution Agreements**
- Strength lies in taking a product from **conceptualization to commercialization**
- **64** Approved ANDAs with **207** strengths
- **23** Commercialized ANDAs with **54** strengths

AMERISYN

Senores Pharmaceuticals Inc.

ZORAYA PHARMACEUTICALS

CDMO / CMO

Business Model

Customized formulation, development & manufacturing capabilities for customers

- **Partner with CDMO customers early** in the drug development process
- **Recurring Revenue** with **Steady & Predictable Cash Flows**
- Contracts for more than **40** products in **US, Canada, UK, South Africa, UAE, Israel, Denmark, Saudi Arabia & Vietnam.**
- Eligible for manufacturing formulations having **controlled substances**
- **Complied** for **catering** to **government supplies** in the **US**

APNAR PHARMA PVT. LTD.
(A subsidiary of Senores Pharmaceuticals Ltd.)

AAVIS PHARMACEUTICALS

Pharmaceutical companies increasingly favor partnering with one-stop-shop solution providers that seamlessly integrate both development and manufacturing services

Distinct Specialty & Complex Product Portfolio Built in a Short Span for Regulated Markets

Demonstrated Capability to Propel Products from Conception to Commercialization

Product Identification

- Data Analysis – IQVIA, Symphony & Other Data
- Competitive Landscape
- Product Feasibility
- CGT Applicability

2-3 Months

Product Development

- R&D to establish API Equivalency
- Formulation Development
- BE Studies
- Stability Testing

18-20 Months

Commercial

Partner Finalization	Concurrent Process
Dossier Compilation	1-2 Months
Filing	Immediately post-compilation
Approval	10-15 Months post-filing
Launch	Immediately post-approval



Amerisyn – Unlocking the US Government Pharmaceutical Market

AMERISYN

The Joint Venture is with a team of Veterans of Army and Air Force.



The team comes with a experience of a decade in Government procurement across Pharmaceuticals, Healthcare and Defence sectors.



The Joint venture has been established to bypass the complex, high barrier market while collaborating with the masters.



Direct supplies to the US Federal government through the Department of Veteran Affairs, Department of Defence, Department of Troop Support etc.



Participating in govt. procurements like VA, FSS & DAPA contracts.



There are nearly 1200 products that the US govt. procures through these various programs including veteran affairs which accounts to $28 Bn out of $145 Bn



Zoraya – A step towards Forward Integration

ZORAYA PHARMACEUTICALS

Partnered with a company with 15 years of on-field experience in direct marketing.

The subsidiary has been established to market the products while making a shift from B2B to B2C channel

Acts as a bridge for India-to-U.S. pharma expansion, strengthening Senores' international credibility.

Existing sales and distribution platform allows immediate access to buyers of Generic and branded prescription drug in the US market



Zoraya is Senores' strategic U.S. anchor, designed to accelerate drug development, regulatory compliance, and market expansion in the US.

The strategic initiative will strengthen our forward integration.

Presence in the Emerging & Mid-Tier Markets with Portfolio including Specialty and Niche Products

40+
Countries Marketed

1,502
Total Products

558
Product Registrations

944
Product Applications Filed



109 | 14
Registered | Filed



196|445
Registered | Filed



44 |172
Registered |Filed



206 | 298
Registered | Filed



3|14
Registered |Filed

Entered EU and Other Mid-Tier Markets with 15 Approved Products as of September 2026

Special Focus

Niche & Specialty patented products in the US with early launch opportunity in Emerging Markets

Sugammadex



Ferric Carboxymaltose



Tofacitinib



Sacubitril + Valsartan



Apixaban



Eltrombopag Olamine



Diverse Business Models

- **P2P Model**
- **Distributor Model**
- **CDMO Model**
- **Own Brands**

Top Emerging Markets

Philippines | Peru | Ghana | Nigeria | Myanmar | Guatemala | Kenya

Branded Generics Business – Key Highlights

60+ Products Launched

100+ Total Employees

200+ Hospitals Served

Key Partners

AIIMS Bathinda

Apollo HOSPITALS

SAL HOSPITAL

pgi

DPU SUPER SPECIALTY HOSPITAL (A Unit of Dr. D.Y. Patil Medical College, Hospital & Research Centre) PIMPRI, PUNE

PARKVIEW SUPER SPECIALITY HOSPITAL

AAKASH HOSPITAL

TATA MEDICAL CENTER

HIMALAYAN HOSPITAL A Constituent Unit of Swami Rama Himalayan University

YASHODHARA SUPER SPECIALITY HOSPITAL REDEFINING PATIENT CARE

Professional and Experienced Management Team (1/2)



Swapnil Jatinbhai Shah
Promoter & Managing Director

- Nearly 2 decades of experience in the pharma sector
- Part of the core management team & leads overall company functions: product portfolio, corporate strategy, business development, strategic management



Sanjay Shaileshbhai Majmudar
Chairman & Non-Executive, Non- Independent Director

- 40+ years of experience
- Director on the board of AIA Engineering Ltd., Ashima Ltd., M&B Engineering Ltd. & Welcast Steels Ltd.



Deval Rajnikant Shah
Whole-Time Director & CFO

- 40+ years of experience in Pharma, Engineering & Chartered Accountancy
- Previously associated with SAI Consulting Engineers Pvt. Ltd. as CFO



Chetan Bipinchandra Shah
Whole-Time Director & COO

- 25+ years of experience in Pharma
- Previously associated with Torrent Pharma & Cadila Pharma. Also associated with Reliance Retail Ltd., Reliance Fresh Ltd. & Reliance Corporate IT Park Ltd.



Jitendra Babulal Sanghvi Non-Executive, Non-Independent Director

- 17+ years of Total experience
- Spearheading Ratnatris Pharmaceuticals as the Director for nearly two decades, since Aug 11, 2009.



Ashokkumar Vijaysinh Barot
Promoter, Non-Executive, Non- Independent Director

- 21+ years of Pharmaceutical experience
- Non-Executive Director on the board of Di-Cal Pharma Pvt. Ltd. Since Nov 6, 2008. Registered pharmacist with the state pharmacy council of Gujarat

Professional and Experienced Management Team (2/2)



Jignesh Desai
President - Finance

- 30+ years of experience in finance and accounting
- Qualified CA by profession
- Previously associated with Cadila Pharmaceuticals, Gokul Refoil & Solvent, Zydus Cadila, and Ashima Denim.



Gautam Shah
President - US Operations

- 30+ years of experience in pharmaceutical industry
- Held leadership roles at leading pharmaceutical companies like Cipla, Sun Pharma, Caraco Pharmaceutical, Dow Corning, Accord Healthcare, etc.



Jatin Gajjar
Chief Technology Officer

- 30+ years of experience in pharmaceutical technology, manufacturing operations, and product development
- Previously associated with Sun Pharmaceutical Industries, Alembic, Zydus Cadila, Torrent Pharma and Aventis Pharma



H. S. Shaktawat
Assistant Vice President - Human Resources

- 25+ years of experience in strategic HR leadership, talent management, and organizational development.
- Previously associated with Sanghi Industries, Cadila Pharmaceuticals, Torrent Pharmaceuticals, Ratnamani Metals & Tubes.



Deepak Jain
Vice President Regulatory Affairs

- Nearly 2 decades of Pharmaceutical experience
- Previously Associated with Cadila Healthcare Ltd. as Deputy General Manager



Sanjay Moralwar
Head - IT

- 36+ years of experience
- Previously associated with CMS Computers Pvt. Ltd, Bajaj Auto Limited, Torrent Pharmaceuticals and Zydus Lifesciences.




Mehul Patel
Vice President – Techno Commercial

- Nearly 2 decades in Formulation Development, technology transfer, and launch execution for Complex Oral Solid products.
- Previously associated with Zydus, Cadila, Wockhardt, etc.

Strong R&D Capabilities Driving Differentiated Product Portfolio

Oral Solids | ORS | Injectables | Oral Liquids | API









R&D Site 1 - USA

In-House R&D in US for Controlled Substances

R&D Site 2 - India

Consolidating R&D activities at Ahmedabad. R&D Centre spread around 11,750 sq. ft

R&D Site 3 - India

Multi-dosage form R&D capabilities and a state-of-the-art Quality Control laboratory for testing and release of all finished products

Research

Internal research Information available on subscribed databases

Team

107 people & 3 members having doctoral qualifications

Margin

The focus on R&D has allowed the company to maintain high profit margins compared to its industry peers

Accredited FDF Manufacturing Facilities (1/2)

Atlanta Facility

Facility

3
Manufacturing Lines

185,300 Sq. Ft.
Total Area



OSD

1.5 Bn units
Annual Installed Capacity

Strong Regulatory Track Record

USFDA Approved — **5 USFDA|** Received **no Form 483** & **8 Customer Audits**

DEA Compliant — **Eligible** for **Manufacturing Controlled Substances**

BAA Compliant — Ability to **caters to Government Supplies**

Ahmedabad, Chhatral Facility



378,943 Sq. Ft.
Total Area

12
Manufacturing Lines

4
Dosage Forms

General Oral Dosage	Injectables	Beta Lactum Orals
1,397.96 Mn Annual Installed Capacity	**49.92 Mn** Annual Installed Capacity	**511.68 Mn** Annual Installed Capacity

Facility Approvals

KUWAIT — MOH	CAMBODIA — MOH	TANZANIA — MOH	IVORY COAST — DPM	KENYA — PPB
PHILIPPINES — FDA	NIGERIA — NFDAC	PERU — DIGEMID	ZAMBIA — MOH	LIBERIA — MOH

Accredited FDF Manufacturing Facilities (2/2)

Apnar Pharma Plant

- ✓ Manufacturing facility commenced in 2021 & **USFDA Approval received in September 2022 & in September 2026.**
- ✓ 2 land parcel available of total land area of **~49,250 Sq. Mts**.
- ✓ Facility constructed on 1 plot (~4,500 Sq. Mts) with construction of ~40,000 Sq. Ft. Larger plot with ample land **available for future expansion**
- ✓ Employees Strength: **150+ Employees**
- ✓ The facility integrates manufacturing with strong multi-dosage form **R&D capabilities** and an advanced **Quality Control Lab** dedicated to testing and releasing all finished products.
- ✓ Facility is compliant with **clean rooms** for expansion into **other dosage forms**



Tablets	Capsules	Bottles
275 Mn Annual Installed Capacity Expandable up to **600 Mn**	**225 Mn** Annual Installed Capacity Expandable up to **500 Mn**	**16 Mn** Annual Installed Capacity Expandable up to **32 Mn**

Strong Regulatory Approvals

- **USFDA**
- **MHRA**
- **Health Canada**

Accredited API Manufacturing Facilities

Senores API Plant I & II

- ✓ **GMP and WHO-GMP Approved sites**
- ✓ Land parcel of **15,134 sq. ft**. and **230,000 sq. ft**. respectively.
- ✓ Employee Strength: **110+ Employees**
- ✓ The facility integrates manufacturing with an advanced **Quality Control Lab** dedicated to testing and releasing all products.
- ✓ **17+** Products already **commercialized**.
- ✓ **5+** Products in **development**.
- ✓ **3 DMFs** under finalization to be filed for triggering the **USFDA audit**.



Unit I	Unit II
25 MT Annual Installed Capacity	**144 MT** Annual Installed Capacity

The API plant II is approvable by USFDA

Great Place to Work with Active Member of Globally recognized Pharma Associations

Great Place To Work Certified



We're Great Place To Work® Certified™

Active Member of Various **Globally Recognized Pharmaceutical Associations & Working Bodies**

FICCI

ASSOCHAM
Ideate · Innovate · Impact

CII
Confederation of Indian Industry

cible
Pursuing Infinite Opportunities
Association of Biotechnology Led Enterprises

GCCI
GUJARAT CHAMBER OF COMMERCE & INDUSTRY

pharmexcil

IDMA

THE INDIAN PHARMACEUTICAL ASSOCIATION (IPA)
...CRUSADE FOR THE PROFESSION

FOPE®
Federation Of Pharma Entrepreneurs

SENORES PHARMACEUTICALS LIMITED

CONTACT US

Senores Pharmaceuticals Limited

CIN: L24290GJ2017PLC100263

Mr. Deval Shah – Whole Time Director & CFO

investors@senorespharma.com

Strategic Growth Advisors Private Limited

CIN: U74140MH2010PTC204285

Mr. Sagar Shroff / Mr. Tanay Shah

sagar.shroff@sgapl.net / tanay.shah@sgapl.net

+91 98205 19303 / +91 98333 91899